Abstract: The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Abstract: The present invention relates to novel proteins that specifically bind to complement factor H (CFH). The present invention further relates to methods of production of CFH, in particular purification of CFH. The novel CFH binding ligands of the present invention are advanced and powerful tools because they allow methods of purification of CFH via affinity chromatography.

Abstract: The present invention relates to new type II collagen alpha I chain specific binding proteins. The invention further refers to type II collagen binding proteins further fused to or conjugated to a therapeutically or diagnostically active component. Further aspects of the invention cover the use of these type II collagen binding proteins in medicine.

Abstract: The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona vims 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Abstract: The present invention relates to the field of protein purification and relates in particular to novel proteins that bind to the soluble part of fibroblast growth factor receptor 3 (sFGFR3). The invention further relates to fusion proteins comprising novel proteins that bind to sFGFR3. In addition, the invention relates to affinity matrices comprising the sFGFR3 binding proteins of the invention. The invention also relates to a use of these sFGFR3 binding proteins or affinity matrices for affinity purification of sFGFR3 nd to methods of affinity purification of sFGFR3 using the sFGFR3 binding proteins of the invention. Further uses relate to analytical methods for the determination of SFGFR3 in liquids.

Abstract: The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.